566
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Assessment of chemical modifications of sites in the CDRs of recombinant antibodies : Susceptibility vs. functionality of critical quality attributes

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Modifications like asparagine deamidation, aspartate isomerization, methionine oxidation, and lysine glycation are typical degradations for recombinant antibodies. For the identification and functional evaluation of antibody critical quality attributes (CQAs) derived from chemical modifications in the complementary-determining regions (CDRs) and the conserved regions, an approach employing specific stress conditions, elevated temperatures, pH, oxidizing agents, and forced glycation with glucose incubation, was applied. The application of the specific stress conditions combined with ion exchange chromatography, proteolytic peptide mapping, quantitative liquid chromatography mass spectrometry, and functional evaluation by surface plasmon resonance analysis was adequate to identify and functionally assess chemical modification sites in the CDRs of a recombinant IgG1. LC-Met-4, LC-Asn-30/31, LC-Asn-92, HC-Met-100c, and HC Lys-33 were identified as potential CQAs. However, none of the assessed degradation products led to a complete loss of functionality if only one light or heavy chain of the native antibody was affected.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Strategies and challenges for the next generation of therapeutic antibodies.

          Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

            The development of bispecific antibodies has attracted substantial interest, and many different formats have been described. Those specifically containing an Fc part are mostly tetravalent, such as stabilized IgG-scFv fusions or dual-variable domain (DVD) IgGs. However, although they exhibit IgG-like properties and technical developability, these formats differ in size and geometry from classical IgG antibodies. Thus, considerable efforts focus on bispecific heterodimeric IgG antibodies that more closely mimic natural IgG molecules. The inherent chain association problem encountered when producing bispecific heterodimeric IgG antibodies can be overcome by several methods. While technologies like knobs-into-holes (KiH) combined with a common light chain or the CrossMab technology enforce the correct chain association, other approaches, e.g., the dual-acting Fab (DAF) IgGs, do not rely on a heterodimeric Fc part. This review discusses the state of the art in bispecific heterodimeric IgG antibodies, with an emphasis on recent progress.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Identification of multiple sources of charge heterogeneity in a recombinant antibody

                Bookmark

                Author and article information

                Journal
                MAbs
                MAbs
                MABS
                mAbs
                Landes Bioscience
                1942-0862
                1942-0870
                01 March 2014
                17 January 2014
                17 January 2014
                : 6
                : 2
                : 327-339
                Affiliations
                [1 ]Pharma Technical Development Penzberg; Roche Diagnostics GmbH; Penzberg, Germany
                [2 ]Pharma Research and Early Development; Roche Diagnostics GmbH; Penzberg, Germany
                [3 ]Pharma Technical Development Basel; F. Hoffmann-La Roche Ltd; Basel, Switzerland
                Author notes
                [* ]Correspondence to: Patrick Bulau, Email: patrick.bulau@ 123456roche.com
                Article
                2013MABS0496R 27876
                10.4161/mabs.27876
                3984323
                24441081
                81a6ea45-8185-4c54-a92e-dc1a5874cbe3
                Copyright © 2014 Landes Bioscience

                This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

                History
                : 19 December 2013
                : 15 January 2014
                : 15 January 2014
                Categories
                Report

                Immunology
                protein degradation,deamidation,oxidation,glycation,recombinant antibodies,mass spectrometry,critical quality attributes,quality by design,developability

                Comments

                Comment on this article